Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis
Issue Date
2014-04Author
Sestak, Joshua
Sullivan, Bradley P.
Thati, Shara
Northrup, Laura Ann
Hartwell, Brittany
Antunez, Lorena
Forrest, M. Laird
Vines, Charlotte M.
Siahaan, Teruna J.
Berkland, Cory J.
Publisher
Nature Publishing Group
Type
Article
Article Version
Scholarly/refereed, publisher version
Metadata
Show full item recordAbstract
Autoimmune diseases such as multiple sclerosis (MS) are typified by the misrecognition of self-antigen and the clonal expansion of autoreactive T cells. Antigen-specific immunotherapies (antigen-SITs) have long been explored as a means to desensitize patients to offending self-antigen(s) with the potential to retolerize the immune response. Soluble antigen arrays (SAgAs) are composed of hyaluronic acid (HA) cografted with disease-specific autoantigen (proteolipid protein peptide) and an ICAM-1 inhibitor peptide (LABL). SAgAs were designed as an antigen-SIT that codeliver peptides to suppress experimental autoimmune encephalomyelitis (EAE), a murine model of MS. Codelivery of antigen and cell adhesion inhibitor (LABL) conjugated to HA was essential for SAgA treatment of EAE. Individual SAgA components or mixtures thereof reduced proinflammatory cytokines in cultured splenocytes from EAE mice; however, these treatments showed minimal to no in vivo therapeutic effect in EAE mice. Thus, carriers that codeliver antigen and a secondary “context” signal (e.g., LABL) in vivo may be an important design criteria to consider when designing antigen-SIT for autoimmune therapy.
Description
This is the published version. Copyright 2014 Nature Publishing Group.
Collections
Citation
Sestak, Joshua O., Bradley P. Sullivan, Sharadvi Thati, Laura Northrup, Brittany Hartwell, Lorena Antunez, M. Laird Forrest, Charlotte M. Vines, Teruna J. Siahaan, and Cory Berkland. "Codelivery of Antigen and an Immune Cell Adhesion Inhibitor Is Necessary for Efficacy of Soluble Antigen Arrays in Experimental Autoimmune Encephalomyelitis." Molecular Therapy — Methods & Clinical Development Mol Ther Methods Clin Dev 1 (2014): 14008. doi: 10.1038/mtm.2014.8.
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.